CAJ | 학술논문

目的：观察新加良附方联合5-氟尿嘧啶（5-Fu）对人胃癌细胞（SGC-7901）裸鼠移植瘤生长抑制作用及其对肿瘤组织中存活素（Survivin）、半胱氨酸天冬氨酸蛋白酶3（Caspase-3）蛋白表达的影响。方法建立移植性人胃癌细胞（SGC-7901）裸鼠移植瘤模型，随机分为模型对照、5-Fu组及新加良附方高、中、低剂量组，联合给药组（新加良附中剂量＋5-Fu）6组。连续给药10 d，计算肿瘤抑制率，检测Survivin、Caspase-3蛋白表达。结果5-Fu组，新加良附方高、中、低剂量组和联合给药组抑瘤率分别为55.03%、56.38%、41.23%、23.09%、60.28%。与模型对照组、5-Fu组、新加良附方高剂量比较，联合用药组抑瘤率较高，差异有统计学意义（P＜0.05）。与模型对照组Caspase-3[（18464.71±7537.01）、Suvivin（63449.4±50498.8）]比较，联合给药组可上调肿瘤组织Caspase-3蛋白（77539.74±50912.5）表达、下调Suvivin 蛋白（35709.1±10404.4）（，P＜0.05或0.01）；与5-Fu组Caspase-3[（47198.89±10751.2）、Suvivin（37016.8±6024.4）]、新加良附高剂量组[Caspase-3（44213.57±7041.6）、Suvivin（38811.1±7313.0）]比较，联合给药组Caspase-3蛋白表达升高（P＜0.05）、Survivin蛋白表达下降（P＜0.05）。结论联合给药组抑瘤率、调节Caspase-3、Survivin表达均优于新加良附高剂量组、5-Fu组，两药协同更有优势。
목적：관찰신가량부방연합5-불뇨밀정（5-Fu）대인위암세포（SGC-7901）라서이식류생장억제작용급기대종류조직중존활소（Survivin）、반광안산천동안산단백매3（Caspase-3）단백표체적영향。방법건립이식성인위암세포（SGC-7901）라서이식류모형，수궤분위모형대조、5-Fu조급신가량부방고、중、저제량조，연합급약조（신가량부중제량＋5-Fu）6조。련속급약10 d，계산종류억제솔，검측Survivin、Caspase-3단백표체。결과5-Fu조，신가량부방고、중、저제량조화연합급약조억류솔분별위55.03%、56.38%、41.23%、23.09%、60.28%。여모형대조조、5-Fu조、신가량부방고제량비교，연합용약조억류솔교고，차이유통계학의의（P＜0.05）。여모형대조조Caspase-3[（18464.71±7537.01）、Suvivin（63449.4±50498.8）]비교，연합급약조가상조종류조직Caspase-3단백（77539.74±50912.5）표체、하조Suvivin 단백（35709.1±10404.4）（，P＜0.05혹0.01）；여5-Fu조Caspase-3[（47198.89±10751.2）、Suvivin（37016.8±6024.4）]、신가량부고제량조[Caspase-3（44213.57±7041.6）、Suvivin（38811.1±7313.0）]비교，연합급약조Caspase-3단백표체승고（P＜0.05）、Survivin단백표체하강（P＜0.05）。결론연합급약조억류솔、조절Caspase-3、Survivin표체균우우신가량부고제량조、5-Fu조，량약협동경유우세。
Objective To observe the effect of Xinjia-Liangfu(XJLF)formula on human gastric cancer(SGC-7901)tumor growth in nude mice and its impact on survivinand Caspase-3 expression in tumor tissue. Methods The animal model of SGC-7901 xenografted nude mice was established, and all the mice were randomly divided into 6 groups, namely model control group, 5-Fu group, XJLF formula high-dose group, XJLF formula medium-dose group , XJLF formula low-dose group and drug combination group(XJLFformula medium-dose and 5-Fu). After 10 days of continuous treatment, tumor inhibition rate was calculated and the expression of Survivin and Caspase-3 was detected by immunohistochemistry techniques. Results The tumor inhibition rates of 5-Fu group, XJLF formula high-dose group, XJLF formula medium-dose group, XJLF formula low-dose group and drug combination group were 55.03%, 56.38%, 41.23%, 23.09%and 60.28%respectively, and the tumor inhibition rate of drug combination group was significantly increased compared to the model control group(P<0.05), 5-Fu group(P<0.05)and XJLF high-dose group(P<0.05) Meanwhile, the Caspase-3 expression was significantly up-regulated and the Survivin expression was significantly down-regulated in drug combination group(Caspase-3 was 77 539.74±50 912.5, Suvivin was 35 709.1±10404.4)compared to the model control group(Caspase-3 was 18 464.71±7 537.01,Suvivin was 63 449.4±50 498.8), P<0.05 or 0.01, 5-Fu groupCaspase-3 was (47 198.89±10 751.2), Suvivin was(37 016.8±6 024.4), P<0.05 or 0.01and XJLF formula high-dose groupCaspase-3was (44213.57±7041.6), Suvivin was (38811.1±7313.0)respectively. Conclusion The tumor inhibition rate of drug combination group was higher than XJLF formula high-dose group and 5-Fu group. Also combination group hadstronger effect compared to model control group in terms of down-regulation of Caspase-3 expression and up-regulation of Survivin expression, which indicates a benefit ofXJLF and 5-Fu combination treatment.